#United States #New York #Class Action #Gross Law Firm #Gossamer Bio

Gossamer Bio, Inc. Shareholder Alert

Investors in Gossamer Bio, Inc. (NASDAQ: GOSS) are encouraged to act swiftly following recent market developments that have led to considerable losses. The Gross Law Firm has issued a notice requesting affected shareholders to come forward, possibly to lead a class-action lawsuit.

The timeline for this collapse is critical; the class period in question spans from June 16, 2025, to February 20, 2026. During this time, Gossamer Bio reportedly misled investors with overly optimistic statements about their Phase 3 PROSERA study, claims which later proved unfounded. Recent disclosures revealed that the study did not meet its primary objective, leading to a dramatic decline in stock value.

On February 23, 2026, Gossamer's shares fell from $2.13 to $0.42 in a single day, representing an astonishing drop of over 80%. This significant loss came after the company's announcement regarding the results of the PROSERA study, which failed to show the expected improvements in patient outcomes. The firm attributed these disappointing results to an advantageous performance by the placebo group at certain Latin American testing sites, indicating that this specific population was not adequately accounted for in the study controls.

Calls to Action for Shareholders
Shareholders who purchased share during the specified class period are urged to register with the Gross Law Firm as soon as possible. Registering is essential to explore your options for participation in the lawsuit and possibly recover losses suffered due to the misleading information provided by Gossamer Bio.

The deadline to register as a lead plaintiff is June 1, 2026. Importantly, being a lead plaintiff is not a prerequisite for participation in any recovery process from this case. All registered shareholders will receive regular updates on the case's status, ensuring they are informed throughout the legal proceedings.

Why Choose The Gross Law Firm?
The Gross Law Firm is recognized for its steadfast commitment to safeguarding investor rights against deceptive practices in the corporate realm. They actively seek to hold companies accountable for practices that artificially inflate stock prices through misinformation. If you have faced losses tied to Gossamer Bio's mismanagement or misrepresentation, this legal avenue may be your opportunity to seek justice.

For those wanting to find out more or for immediate registration, please contact the Gross Law Firm directly at their New York office:

Contact Information
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Phone: (646) 453-8903
Email: [email protected]

Investors must not delay in asserting their rights. For more details, please visit their official site here. Protect your investment and ensure that you are informed about your options to recover damages incurred during this period of uncertainty for Gossamer Bio, Inc.